Biotech Values

[Robert C Jonson]

Whoever designed this ph2 trial in 2nd line NSCLC, whatever credential he had, even if he were God, his assumptions were incorrect, otherwise the trial would have met both primary and secondary endpoints.


jq1234, Bavi has been found to work more slowly than other drugs in trial, and I wonder if that would have any bearing on its stat. sig. performance? If the ORR, PFS, measurements and reporting were delayed longer after completion of enrollment, could that make a difference?
I know the company addressed this factor at the completion of their HCV trial.